PMC3975752_01
Brain MRI (a-c) of 3 NSCLC patients before (top row) and after (bottom row) gefitinib treatment. a On contrast enhanced T1 weighted image, a small peripheral enhancing nodule in the left occipital lobe is identified (arrow). b A small, well-defined enhancing round nodule in the left occipital lobe is identified (arrow). c A small enhancing nodule in the right periventricular deep white matter is identified (arrow).
cro-0007-0149-g01.jpg
PMC3975752_03_cro-0007-0149-g01.jpg
F1
After 5 months of gefitinib treatment (250 mg/day), a follow-up brain MRI showed no brain parenchymal metastatic lesions (fig. 1c).
PMC3975752_02
Brain MRI (a-c) of 3 NSCLC patients before (top row) and after (bottom row) gefitinib treatment. a On contrast enhanced T1 weighted image, a small peripheral enhancing nodule in the left occipital lobe is identified (arrow). b A small, well-defined enhancing round nodule in the left occipital lobe is identified (arrow). c A small enhancing nodule in the right periventricular deep white matter is identified (arrow).
cro-0007-0149-g01.jpg
PMC3975752_03_cro-0007-0149-g01.jpg
F1
After 5 months of gefitinib treatment (250 mg/day), a follow-up brain MRI showed no brain parenchymal metastatic lesions (fig. 1c).
PMC3975752_03
Brain MRI (a-c) of 3 NSCLC patients before (top row) and after (bottom row) gefitinib treatment. a On contrast enhanced T1 weighted image, a small peripheral enhancing nodule in the left occipital lobe is identified (arrow). b A small, well-defined enhancing round nodule in the left occipital lobe is identified (arrow). c A small enhancing nodule in the right periventricular deep white matter is identified (arrow).
cro-0007-0149-g01.jpg
PMC3975752_03_cro-0007-0149-g01.jpg
F1
After 5 months of gefitinib treatment (250 mg/day), a follow-up brain MRI showed no brain parenchymal metastatic lesions (fig. 1c).